In April 2025, our company obtained the energy management system certification for the second time, which complies with the standards GB/T 23331-2020, ISO 50001:2008, and RB/T 114-2023. Since 2020, the company has passed the “Three Certifications” of environmental management system, occupational health and safety management system, and energy management system, and has been selected as one of the fifth batch of “Green Factories” by the Ministry of Industry and Information Technology of the People’s Republic of China, and has been awarded the Five-star Rating of Green Credit in Daxing District. We will actively respond to the national policies aimed at achieving “Carbon Peak” and “Carbon Neutrality”, continuously improve our EHS management capability, explore new techniques and paths for low-carbon, energy saving, emission reduction and consu...

In October 2024, the Ministry of Health of the Russian Federation released the Clinical Guidelines for Non-alcoholic Fatty Liver Diseases developed by professional organizations such as the Liver Research Society, the Gastroenterology Association, and the Endocrinology Association, and approved by the Scientific and Practical Council of the Ministry of Health. “For NAFLD (NASH) patients with moderate to severe elevated ALT, it is recommended to prescribe a dose of 75-150mg/day of Bicyclol for 24 weeks to reduce disease activity” (Evidence level I, Recommendation B). Bicyclol was registered and marketed in Russia in August 2015, and has been included in Guidelines for Diagnosis, Treatment, and Prevention of Viral Hepatitis in Armed Forces, Drug-Induced Liver Injuries (Clinical Guidelines for Physicians) and Clinical Guideline...

In September 2024, Journal of Practical Hepatology and Journal of Clinical Hepatology (both are listed as the key magazine of China technology), published the Multidisciplinary Expert Consensus on the Prevention and Treatment of Inflammatory Liver Injury with Bicyclol. Inflammatory liver injury is the initiating factor for various chronic liver diseases. The diagnosis and treatment of liver injury often require multidisciplinary discussions and joint decision-making. The preparation of the Consensus is organized by the Hepatology Group of the Chronic Disease Management Branch of the China Medicinal Biotechnology Association. Domestic experts from relevant disciplines, based on the guidelines/consensus/clinical pathways and evidence-based medicine for liver disease diagnosis and treatment with reference to the clinical practice in China, summarize the pro...